Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 297 | 2020 |
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma P Armand, S Rodig, V Melnichenko, C Thieblemont, K Bouabdallah, ... Journal of Clinical Oncology 37 (34), 3291, 2019 | 251 | 2019 |
BCL-2 as therapeutic target for hematological malignancies GF Perini, GN Ribeiro, JV Pinto Neto, LT Campos, N Hamerschlak Journal of hematology & oncology 11, 1-15, 2018 | 188 | 2018 |
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase … J Kuruvilla, R Ramchandren, A Santoro, E Paszkiewicz-Kozik, ... The Lancet Oncology 22 (4), 512-524, 2021 | 166 | 2021 |
Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy AR Mato, LE Roeker, R Jacobs, BT Hill, N Lamanna, D Brander, ... Clinical Cancer Research 26 (14), 3589-3596, 2020 | 106 | 2020 |
Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma ML Wang, W Jurczak, M Jerkeman, J Trotman, PL Zinzani, D Belada, ... New England Journal of Medicine 386 (26), 2482-2494, 2022 | 103 | 2022 |
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies LE Roeker, TA Eyre, MC Thompson, N Lamanna, AR Coltoff, MS Davids, ... Blood, The Journal of the American Society of Hematology 138 (18), 1768-1773, 2021 | 59 | 2021 |
Challenges and opportunities in primary CNS lymphoma: A systematic review MN Kerbauy, FY Moraes, BH Lok, J Ma, LN Kerbauy, DE Spratt, ... Radiotherapy and Oncology 122 (3), 352-361, 2017 | 55 | 2017 |
How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation GF Perini, T Fischer, RD Gaiolla, TB Rocha, M Bellesso, LLC Teixeira, ... Hematology, Transfusion and Cell Therapy 42 (2), 103-110, 2020 | 42 | 2020 |
A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: the first case report in Latin America FF José, LN Kerbauy, GF Perini, DI Blumenschein, D da Cunha Pasqualin, ... Medicine 96 (13), e6271, 2017 | 39 | 2017 |
KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). J Kuruvilla, R Ramchandren, A Santoro, E Paszkiewicz-Kozik, ... Journal of Clinical Oncology 38 (15_suppl), 8005-8005, 2020 | 38 | 2020 |
Brentuximab vedotin in CD30+ lymphomas GF Perini, B Pro Biologics in therapy 3, 15-23, 2013 | 34 | 2013 |
Molecular biology of Philadelphia-negative myeloproliferative neoplasms PV Campregher, FPS Santos, GF Perini, N Hamerschlak Revista Brasileira de Hematologia e Hemoterapia 34, 150-155, 2012 | 30 | 2012 |
Central nervous system prophylaxis in peripheral T-cell lymphoma B Pro, G Perini Blood, The Journal of the American Society of Hematology 115 (26), 5427-5427, 2010 | 28 | 2010 |
Síndrome pré-menstrual e desempenho escolar MS Approbato, CDA Silva, GF Perini, TG Miranda, TD Fonseca, ... Revista Brasileira de Ginecologia e Obstetrícia 23, 459-462, 2001 | 28 | 2001 |
Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients—An analysis from the Brazilian Hodgkin Lymphoma Registry I Biasoli, N Castro, M Delamain, T Silveira, J Farley, B Pinto Simões, ... International journal of cancer 142 (5), 883-890, 2018 | 25 | 2018 |
Pembrolizumab in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL): data from the Keynote-013 and Keynote-170 studies P Armand, SJ Rodig, V Melnichenko, C Thieblemont, K Bouabdallah, ... Blood 132, 228, 2018 | 21 | 2018 |
Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry I Biasoli, N Castro, M Delamain, T Silveira, J Farley, BP Simões, C Solza, ... Hematological Oncology 36 (1), 189-195, 2018 | 19 | 2018 |
Nilotinib post-liver transplantation for acute hepatic failure related to imatinib GF Perini, FPS Santos, V Funke, J Ruiz, BHF Neto, N Hamerschlak Leukemia Research 33 (12), e234-e235, 2009 | 19 | 2009 |
BCL-2 inhibition as treatment for chronic lymphocytic leukemia GF Perini, CCP Feres, LLC Teixeira, N Hamerschlak Current Treatment Options in Oncology 22 (8), 66, 2021 | 17 | 2021 |